Molle Inge Van
Inventor
Stats
- 0 US patents issued
- 4 US Applications filed
- most recent filing
This is official USPTO record data
Details
- 0 US Patents Issued
- 4 US Applications Filed
- 157 Total Citation Count
- May 17, 2024 Most Recent Filing
- Jan 11, 2013 Earliest Filing
Work History
| Patent Owner | Applications Filed | Year |
|---|---|---|
| CAMBRIDGE ENTERPRISE LIMITED | 1
| 2013
|
| YALE UNIVERSITY | 1
| 2013
|
| GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 1
| 2013
|
Inventor Addresses
| Address | Duration |
|---|---|
| Brussel, BE | Nov 14, 24 - Nov 14, 24 |
| CAMBRIDGE, GB | May 02, 19 - Sep 26, 24 |
| Cambridge, GB | Dec 04, 14 - Aug 04, 20 |
Technology Profile
| Technology | Matters | |
|---|---|---|
| A61K: | PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES | 4 |
| A61P: | THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS | 1 |
| C07D: | HETEROCYCLIC COMPOUNDS | 3 |
Patents / Publication
| Patents / Publication # | Year of Publication / Issued | Title | Citations |
|---|---|---|---|
| 2024/0376,149 | 2024 | Novel Modulators of GABABR1a | 0 |
| 2024/0317,729 | 2024 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | 0 |
| 10730862 | 2020 | Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase | 4 |
| 2019/0127,359 | 2019 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | 5 |
| 2014/0356,322 | 2014 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | 153 |
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level.
>
Upgrade to our Level for up to -1 portfolios!.